JPS6223725B2 - - Google Patents
Info
- Publication number
- JPS6223725B2 JPS6223725B2 JP13768678A JP13768678A JPS6223725B2 JP S6223725 B2 JPS6223725 B2 JP S6223725B2 JP 13768678 A JP13768678 A JP 13768678A JP 13768678 A JP13768678 A JP 13768678A JP S6223725 B2 JPS6223725 B2 JP S6223725B2
- Authority
- JP
- Japan
- Prior art keywords
- fluorouracil
- anticancer
- compound
- thymidine
- fluorouracils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 34
- 230000001093 anti-cancer Effects 0.000 claims description 23
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 17
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 17
- 229940104230 thymidine Drugs 0.000 claims description 17
- 239000003623 enhancer Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 28
- 229960002949 fluorouracil Drugs 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- -1 butoxymethyl Chemical group 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MGYWDJWGVICAEL-UHFFFAOYSA-N 5-fluoro-3-(oxolan-2-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1OCCC1 MGYWDJWGVICAEL-UHFFFAOYSA-N 0.000 description 3
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 3
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 125000004849 alkoxymethyl group Chemical group 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OUAPULXYUWUOHW-UHFFFAOYSA-N 1-(ethoxymethyl)-5-fluoropyrimidine-2,4-dione Chemical compound CCOCN1C=C(F)C(=O)NC1=O OUAPULXYUWUOHW-UHFFFAOYSA-N 0.000 description 1
- FLMBDTNCANYTCP-UHFFFAOYSA-N 5-fluoro-1,3-bis(oxolan-2-yl)pyrimidine-2,4-dione Chemical compound O=C1N(C2OCCC2)C(=O)C(F)=CN1C1CCCO1 FLMBDTNCANYTCP-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000691 up-and-down procedure Toxicity 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13768678A JPS5564518A (en) | 1978-11-07 | 1978-11-07 | Carcinostatic composition |
| GB7908960A GB2016921B (en) | 1978-03-27 | 1979-03-14 | Anti cancer compositions containing uracil derivatives |
| CH272679A CH639274A5 (de) | 1978-03-27 | 1979-03-23 | Antikrebsmittel. |
| FR7907523A FR2420974A1 (fr) | 1978-03-27 | 1979-03-26 | Medicament a base de derives de l'uracile |
| IT67629/79A IT1119283B (it) | 1978-03-27 | 1979-03-27 | Composizione anti cancro |
| DE2912112A DE2912112C2 (de) | 1978-03-27 | 1979-03-27 | Antikrebs-Präparat |
| US06/552,263 US4650801A (en) | 1978-03-27 | 1983-11-16 | Anti-cancer compositions for delivering 5-fluorouracil |
| US06/932,516 US4914105A (en) | 1978-03-27 | 1986-11-20 | Anti-cancer compositions for delivering 5-fluorouracil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13768678A JPS5564518A (en) | 1978-11-07 | 1978-11-07 | Carcinostatic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5564518A JPS5564518A (en) | 1980-05-15 |
| JPS6223725B2 true JPS6223725B2 (de) | 1987-05-25 |
Family
ID=15204428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13768678A Granted JPS5564518A (en) | 1978-03-27 | 1978-11-07 | Carcinostatic composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5564518A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055493A1 (fr) * | 1997-06-03 | 1998-12-10 | Mori, Takahide | Substances naturelles antitumorales ou antivirales et leur utilisation |
-
1978
- 1978-11-07 JP JP13768678A patent/JPS5564518A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055493A1 (fr) * | 1997-06-03 | 1998-12-10 | Mori, Takahide | Substances naturelles antitumorales ou antivirales et leur utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5564518A (en) | 1980-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2214238C2 (ru) | Фармацевтическая композиция, обладающая противоопухолевым действием со сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты | |
| US20070293468A1 (en) | Anticancer compositions, and methods of making and using the same | |
| JP2019515884A5 (de) | ||
| JPH0430924B2 (de) | ||
| AU2004220205B2 (en) | Antitumor effect potentiator and antitumor agent | |
| PT1757283E (pt) | Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro | |
| EP0500953B1 (de) | Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff | |
| JP2951407B2 (ja) | チアゾフリン及びリバビリンを用いる新生物病の処置方法 | |
| JP2688057B2 (ja) | 抗腺がん剤 | |
| NL194430C (nl) | Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking. | |
| US5534513A (en) | Antitumor potentiator and antitumor composition | |
| JPS6223725B2 (de) | ||
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| US3169091A (en) | Process for inhibiting tumors with substituted pyrazoles | |
| JPH0120128B2 (de) | ||
| JPS6231689B2 (de) | ||
| EA006776B1 (ru) | Фармацевтическая композиция для лечения диабетической невропатии | |
| JPS6257165B2 (de) | ||
| JPS6223723B2 (de) | ||
| JPS6213924B2 (de) | ||
| JPH03502802A (ja) | 抗嘔吐性エルゴリン誘導体 | |
| JPS6231690B2 (de) | ||
| AU609835B2 (en) | Antidiabetic agent | |
| JPS6337767B2 (de) | ||
| JPS6312845B2 (de) |